Earnings summaries and quarterly performance for Orthofix Medical.
Executive leadership at Orthofix Medical.
Massimo Calafiore
Detailed
Chief Executive Officer
CEO
JA
J. Andrés Cedrón
Detailed
Chief Legal Officer
JA
Julie Andrews
Detailed
Chief Financial Officer
LV
Lucas Vitale
Detailed
Chief People and Business Operations Officer
MR
Max Reinhardt
Detailed
President, Global Spine
PF
Patrick Fisher
Detailed
President, Global Orthopedics
Board of directors at Orthofix Medical.
AL
Alan L. Bazaar
Detailed
Director
CR
Charles R. Kummeth
Detailed
Director
JM
Jason M. Hannon
Detailed
Director
JB
John B. Henneman, III
Detailed
Director
ME
Michael E. Paolucci
Detailed
Director
MM
Michael M. Finegan
Detailed
Chair of the Board
SS
Shweta Singh Maniar
Detailed
Director
VL
Vickie L. Capps
Detailed
Director
WB
Wayne Burris
Detailed
Director
Research analysts who have asked questions during Orthofix Medical earnings calls.
CC
Caitlin Cronin
Canaccord Genuity
3 questions for OFIX
Also covers: ATEC, AXGN, BVS +10 more
MB
Mathew Blackman
Stifel
3 questions for OFIX
Also covers: AHCO, ATEC, BBNX +7 more
JW
Jason Wittes
Roth Capital Partners, LLC
2 questions for OFIX
Also covers: ALUR, ARAY, ATEC +13 more
MP
Michael Petusky
Barrington Research
1 question for OFIX
Also covers: ANIK, HAE, HSIC +8 more
Ryan Zimmerman
BTIG
1 question for OFIX
Also covers: ALC, GEHC, GKOS +23 more
Recent press releases and 8-K filings for OFIX.
Orthofix Highlights Q3 2025 Performance and 2026/2027 Growth Strategy
OFIX
Revenue Acceleration/Inflection
Product Launch
New Projects/Investments
- Orthofix reported a strong Q3 2025, exceeding consensus on revenue and EBITDA, with 6% revenue growth and its seventh consecutive quarter of EBITDA margin expansion. The revenue beat was primarily attributed to the timing of international stocking orders shifting from Q4 to Q3, which led the company to maintain its full-year guidance.
- The company is focused on profitable growth, aiming for above-market growth in its US Spine business, which saw +10% procedure growth in Q3 2025. Ongoing distributor transitions are expected to continue driving incremental growth and improve working capital efficiency.
- Orthofix is launching Verata, a new product designed for its 7D enabling technology, with an alpha launch closing at the end of 2025 and a full launch targeted for 2H 2026. Verata is expected to drive incremental growth in 2026 and accelerate into 2027.
- The company targets 300 basis points of gross margin expansion by 2027 through initiatives like supplier consolidation and insourcing. It also aims for mid-teens adjusted EBITDA margin by 2027, up from an implied 10.5% for full-year 2025, with the expansion weighted more towards 2027.
Nov 12, 2025, 3:00 PM
Orthofix Highlights Strong Q3 2025 Results and Future Growth Strategy
OFIX
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Orthofix reported a strong Q3 2025, exceeding consensus on revenue and EBITDA, with 6% revenue growth and 230 basis points of EBITDA margin expansion, marking its seventh consecutive quarter of such expansion.
- The company maintained its Q4 2025 guidance midpoint, attributing the Q3 beat to the earlier-than-expected timing of international stocking orders.
- Management is targeting mid-teens adjusted EBITDA margin by 2027 and 300 basis points of gross margin expansion by 2027, driven by supplier consolidation and insourcing.
- The Virata product line is anticipated to drive growth in H2 2026 and accelerate into 2027, with additional versions planned for future years.
- A new CMS pilot program for Bone Growth Therapy (BGT) starting in January 2026 is projected to have an immaterial annual impact and no change in physician prescribing behavior.
Nov 12, 2025, 3:00 PM
Orthofix Medical Discusses Financial Turnaround, Growth Drivers, and Long-Term Targets at UBS Conference
OFIX
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Orthofix Medical has achieved a significant financial turnaround, reporting seven consecutive quarters of positive EBITDA and moving from over $100 million in free cash flow losses to positive generation.
- The company delivered a solid Q3 performance, including 86% growth in international spine fixation, and is focused on key product launches like Virata (spine) and TruLock Elevate (orthopedics) as growth drivers for 2026 and beyond.
- With an 8% annual R&D investment, Orthofix leverages its 7D Flash Navigation platform, which has led to accounts being 50% ahead of volume commitment in its earn-out program.
- Long-term targets include a 6.5-7.5% net sales CAGR through 2025-2027 and mid-teens adjusted EBITDA by 2027, alongside sustained positive free cash flow.
Nov 11, 2025, 6:15 PM
Orthofix Medical Provides Business Update at UBS Global Healthcare Conference
OFIX
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Orthofix Medical has achieved a significant financial turnaround, moving from a $109 million free cash flow loss to being free cash flow positive and recording seven consecutive quarters of positive EBITDA.
- The company reported a solid third quarter with strong growth, including 25% year-over-year sales growth from its top 30 U.S. Distributor partners and 86% growth in International Spine Fixation.
- Key growth drivers include the upcoming full launch of Vorata in Spine and TRULOC Elevate in Orthopedics in 2026, alongside the successful 7D Flash Navigation Voyager program, which sees accounts 50% ahead of their volume commitment.
- Orthofix has set long-term targets through 2027, aiming for a 6.5% to 7.5% net sales CAGR, mid-teens adjusted EBITDA, and sustained positive free cash flow, supported by disciplined R&D investment (around 8% annually) and strategic product line rationalization.
Nov 11, 2025, 6:15 PM
Orthofix Reports Strong Q3 2025 Results and Updates Full-Year Guidance
OFIX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Orthofix delivered Q3 2025 net sales of $203.4 million, a 6% increase year-over-year, driven by strong performance in its US spine and orthopedics segments.
- The company achieved $24.6 million in pro forma non-GAAP adjusted EBITDA, representing 12.1% of net sales and marking its seventh consecutive quarter of EBITDA margin expansion.
- Key growth drivers included an 8% increase in US spine fixation net sales and 19% growth in US orthopedics, supported by the 7D Flash Navigation System and successful distributor transitions.
- Orthofix narrowed its full-year 2025 pro forma net sales guidance to $810 million-$814 million and raised the bottom end of its adjusted EBITDA guidance to $84 million, with an updated range of $84 million-$86 million.
Nov 4, 2025, 1:30 PM
OFIX Reports Q3 2025 Financial Results
OFIX
Earnings
Revenue Acceleration/Inflection
- Reported net sales for Q3 2025 increased by 4.6% to $205.6 million compared to Q3 2024. Pro forma net sales also grew by 6.3% to $203.4 million for the same period.
- The company reported a net loss of $(22.795) million for Q3 2025, an improvement from a $(27.388) million loss in Q3 2024. This resulted in a net loss per common share of $(0.57) for Q3 2025, compared to $(0.71) in Q3 2024.
- Adjusted EBITDA for Q3 2025 significantly increased to $25.114 million from $19.180 million in Q3 2024, with its percentage of reported net sales rising to 12.2% from 9.8%.
- For the nine months ended September 30, 2025, net cash provided by operating activities improved to $5.650 million from $2.060 million in the prior year period, and free cash flow improved to $(18.099) million from $(24.285) million.
Nov 4, 2025, 1:30 PM
Orthofix Reports Q3 2025 Financial Results and Updates Full-Year Guidance
OFIX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Orthofix Medical Inc. reported Q3 2025 net sales of $205.6 million, or $203.4 million pro forma, representing an increase of 4.6% on a reported basis and 5.7% on a pro forma constant currency basis compared to Q3 2024.
- The company posted a net loss of $(22.8) million, or $(0.57) per share, for Q3 2025, while non-GAAP pro forma adjusted EBITDA increased by $5.4 million to $24.6 million.
- Orthofix generated positive free cash flow of $2.5 million in Q3 2025, marking its seventh consecutive quarter of adjusted EBITDA margin expansion.
- For full-year 2025, the company narrowed its pro forma net sales guidance to $810 million to $814 million and raised the low end of its pro forma non-GAAP adjusted EBITDA guidance to $84 million to $86 million.
Nov 4, 2025, 12:02 PM
Orthofix Reports Third Quarter 2025 Financial Results and Updates Full-Year Guidance
OFIX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Orthofix reported third quarter 2025 net sales of $205.6 million, reflecting a 5% increase on a reported basis compared to the third quarter 2024.
- The company posted a net loss of $(22.8) million, or $(0.57) per share, for the third quarter of 2025.
- Non-GAAP pro forma adjusted EBITDA for Q3 2025 was $24.6 million, an increase of 28.2% over the prior year, marking the seventh consecutive quarter of adjusted EBITDA margin expansion.
- Orthofix generated positive free cash flow of $2.5 million for the third quarter 2025.
- For full-year 2025, the company narrowed its pro forma net sales guidance to $810 million to $814 million and raised the low end of its pro forma adjusted EBITDA guidance to $84 million to $86 million.
Nov 4, 2025, 12:00 PM
Quarterly earnings call transcripts for Orthofix Medical.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more